JP6479854B2 - 医薬組成物のためのスルホキシイミン置換キナゾリン - Google Patents
医薬組成物のためのスルホキシイミン置換キナゾリン Download PDFInfo
- Publication number
- JP6479854B2 JP6479854B2 JP2016566786A JP2016566786A JP6479854B2 JP 6479854 B2 JP6479854 B2 JP 6479854B2 JP 2016566786 A JP2016566786 A JP 2016566786A JP 2016566786 A JP2016566786 A JP 2016566786A JP 6479854 B2 JP6479854 B2 JP 6479854B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- heterocyclyl
- optionally substituted
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *Oc1cc([n]nc2)c2cc1N Chemical compound *Oc1cc([n]nc2)c2cc1N 0.000 description 10
- PFGBPYLGLUTIAY-UHFFFAOYSA-N CC(Oc(c(OC)c1Cl)cc2c1c(Cl)ncn2)=O Chemical compound CC(Oc(c(OC)c1Cl)cc2c1c(Cl)ncn2)=O PFGBPYLGLUTIAY-UHFFFAOYSA-N 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N CN(C)C(OC)OC Chemical compound CN(C)C(OC)OC ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- KHKCXJYIXJUZDV-UHFFFAOYSA-N CN(CCN(CCCOC)C1)C1=O Chemical compound CN(CCN(CCCOC)C1)C1=O KHKCXJYIXJUZDV-UHFFFAOYSA-N 0.000 description 1
- HHHRFYZKJJUCFL-UHFFFAOYSA-N CN(CCN(CCOC)C1)C1=O Chemical compound CN(CCN(CCOC)C1)C1=O HHHRFYZKJJUCFL-UHFFFAOYSA-N 0.000 description 1
- JAEQOSKUYPMJAT-UHFFFAOYSA-N COCCN1CCOCC1 Chemical compound COCCN1CCOCC1 JAEQOSKUYPMJAT-UHFFFAOYSA-N 0.000 description 1
- GZFDUIXPOANTDN-GQUJEBGOSA-N CO[C@H](CO[C@@H]12)[C@H]1OC[C@H]2Oc(cc(cc1)F)c1Nc1ncnc(cc2N=S3(CCCC3)=O)c1c(Cl)c2OC Chemical compound CO[C@H](CO[C@@H]12)[C@H]1OC[C@H]2Oc(cc(cc1)F)c1Nc1ncnc(cc2N=S3(CCCC3)=O)c1c(Cl)c2OC GZFDUIXPOANTDN-GQUJEBGOSA-N 0.000 description 1
- FOGVEYPAPSELLE-LLVKDONJSA-N C[C@H](C(NCC(F)(F)F)=O)Oc(cc(cc1)F)c1Nc(ncnc1cc2N=S(C)(C)=O)c1c(Cl)c2OC Chemical compound C[C@H](C(NCC(F)(F)F)=O)Oc(cc(cc1)F)c1Nc(ncnc1cc2N=S(C)(C)=O)c1c(Cl)c2OC FOGVEYPAPSELLE-LLVKDONJSA-N 0.000 description 1
- XLTNBKHECYNWGU-OVCLIPMQSA-N Cc(cc(c(C#N)c1C)/N=C/N(C)C)c1OC Chemical compound Cc(cc(c(C#N)c1C)/N=C/N(C)C)c1OC XLTNBKHECYNWGU-OVCLIPMQSA-N 0.000 description 1
- KUTMLPLLLJVBCN-UHFFFAOYSA-N IOC1COCC1 Chemical compound IOC1COCC1 KUTMLPLLLJVBCN-UHFFFAOYSA-N 0.000 description 1
- YVPBGTVQPKQWDV-UHFFFAOYSA-N NOCCCN1CCOCC1 Chemical compound NOCCCN1CCOCC1 YVPBGTVQPKQWDV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14167373.1 | 2014-05-07 | ||
| EP14167373 | 2014-05-07 | ||
| PCT/EP2015/059453 WO2015169677A1 (en) | 2014-05-07 | 2015-04-30 | Sulfoximine substituted quinazolines for pharmaceutical compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017514867A JP2017514867A (ja) | 2017-06-08 |
| JP2017514867A5 JP2017514867A5 (enExample) | 2018-09-20 |
| JP6479854B2 true JP6479854B2 (ja) | 2019-03-06 |
Family
ID=50639371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016566786A Expired - Fee Related JP6479854B2 (ja) | 2014-05-07 | 2015-04-30 | 医薬組成物のためのスルホキシイミン置換キナゾリン |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10167296B2 (enExample) |
| EP (1) | EP3140300B1 (enExample) |
| JP (1) | JP6479854B2 (enExample) |
| AU (1) | AU2015257917C1 (enExample) |
| CA (1) | CA2944103A1 (enExample) |
| ES (1) | ES2749186T3 (enExample) |
| WO (1) | WO2015169677A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170066778A1 (en) * | 2015-09-04 | 2017-03-09 | Aunova Medchem LLC | Solubility for target compounds |
| US20190117657A1 (en) * | 2016-03-31 | 2019-04-25 | South Australian Health And Medical Research Institute Limited | Method of inhibiting high fat diet-related conditions |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19712960A1 (de) | 1997-03-27 | 1998-10-01 | Hoechst Ag | Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten |
| SE0102147D0 (sv) | 2001-06-18 | 2001-06-18 | Pharmacia Ab | New methods |
| DE60238929D1 (de) | 2001-10-29 | 2011-02-24 | Boehringer Ingelheim Int | Mnk-kinase-homologe proteine, die an der regulierung der energiehomöostase und dem organellen metabolismus beteiligt sind |
| GB0315587D0 (en) | 2003-07-03 | 2003-08-13 | Univ Dundee | Anti-inflammatory assay and compounds |
| CA2558647C (en) | 2004-04-08 | 2013-05-28 | Dow Agrosciences Llc | Insecticidal n-substituted sulfoximines |
| EP1746099A1 (en) | 2004-12-23 | 2007-01-24 | DeveloGen Aktiengesellschaft | Mnk1 or Mnk2 inhibitors |
| EP1899353A1 (en) * | 2005-06-22 | 2008-03-19 | DeveloGen Aktiengesellschaft | Thienopyrimidines for pharmaceutical compositions |
| MX2008011525A (es) | 2006-03-09 | 2008-09-18 | Pharmacopeia Inc | Inhibidores de mnk2 de 8-heteroarilpurina para el tratamiento de trastornos metabolicos. |
| US8633201B2 (en) * | 2006-04-07 | 2014-01-21 | Boehringer Ingelheim International Gmbh | Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions |
| ATE456565T1 (de) | 2006-06-22 | 2010-02-15 | Biovitrum Ab Publ | Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren |
| EP1889847A1 (en) * | 2006-07-10 | 2008-02-20 | DeveloGen Aktiengesellschaft | Pyrrolopyrimidines for pharmaceutical compositions |
| JP2010527951A (ja) * | 2007-05-24 | 2010-08-19 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | キナーゼ阻害剤としての新規なスルホキシイミン置換型キノリン及びキナゾリン誘導体 |
| EP2331551B1 (en) * | 2008-08-26 | 2016-06-29 | Evotec International GmbH | Thienopyrimidines for pharmaceutical compositions |
| TW201102391A (en) | 2009-03-31 | 2011-01-16 | Biogen Idec Inc | Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use |
| TW201111378A (en) | 2009-09-11 | 2011-04-01 | Bayer Schering Pharma Ag | Substituted (heteroarylmethyl) thiohydantoins |
| UY33241A (es) | 2010-02-26 | 2011-09-30 | Boehringer Ingelheim Int | ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?. |
| JP5575274B2 (ja) | 2010-02-26 | 2014-08-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物のためのｍｎｋｌ／ｍｎｋ２阻害活性を有する４−［シクロアルキルオキシ（ヘテロ）アリールアミノ］チエノ「２，３−ｄ］ピリミジン |
| EP2539343B1 (en) * | 2010-02-26 | 2015-12-30 | Evotec International GmbH | Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions |
| US9170933B2 (en) * | 2010-06-28 | 2015-10-27 | International Business Machines Corporation | Wear-level of cells/pages/sub-pages/blocks of a memory |
| AR088082A1 (es) | 2011-10-13 | 2014-05-07 | Lilly Co Eli | Moduladores selectivos del receptor androgeno |
| CN104507950B (zh) | 2012-05-21 | 2017-03-22 | 拜耳医药股份有限公司 | 噻吩并嘧啶 |
| TW201412740A (zh) * | 2012-09-20 | 2014-04-01 | Bayer Pharma AG | 經取代之吡咯并嘧啶胺基苯并噻唑酮 |
| EP2900671A1 (en) * | 2012-09-26 | 2015-08-05 | Bayer Pharma Aktiengesellschaft | Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseases |
| WO2014072244A1 (en) * | 2012-11-09 | 2014-05-15 | Boehringer Ingelheim International Gmbh | Sulfoximine substituted quinazolines for pharmaceutical compositions |
| ES2653419T3 (es) * | 2013-02-01 | 2018-02-07 | Bayer Pharma Aktiengesellschaft | Pirazolopirimidinilamino-indazoles sustituidos |
| AU2014301295C1 (en) * | 2013-06-28 | 2018-03-15 | Evotec International Gmbh | Sulfoximine substituted quinazolines and their use as MNK1 and/or MNK2 kinase inhibitors |
| ES2693520T3 (es) * | 2013-12-04 | 2018-12-12 | Evotec International Gmbh | Quinazolinas sustituidas con sulfoximina para composiciones farmacéuticas |
-
2015
- 2015-04-30 EP EP15720077.5A patent/EP3140300B1/en active Active
- 2015-04-30 CA CA2944103A patent/CA2944103A1/en active Pending
- 2015-04-30 WO PCT/EP2015/059453 patent/WO2015169677A1/en not_active Ceased
- 2015-04-30 AU AU2015257917A patent/AU2015257917C1/en not_active Ceased
- 2015-04-30 ES ES15720077T patent/ES2749186T3/es active Active
- 2015-04-30 US US15/308,712 patent/US10167296B2/en active Active
- 2015-04-30 JP JP2016566786A patent/JP6479854B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20170260195A1 (en) | 2017-09-14 |
| EP3140300A1 (en) | 2017-03-15 |
| ES2749186T3 (es) | 2020-03-19 |
| JP2017514867A (ja) | 2017-06-08 |
| US10167296B2 (en) | 2019-01-01 |
| AU2015257917C1 (en) | 2019-03-14 |
| CA2944103A1 (en) | 2015-11-12 |
| WO2015169677A1 (en) | 2015-11-12 |
| AU2015257917A1 (en) | 2016-10-27 |
| AU2015257917B2 (en) | 2017-08-17 |
| EP3140300B1 (en) | 2019-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5639197B2 (ja) | 医薬組成物のためのヘテロシクロアルキル含有チエノピリミジン | |
| JP5575275B2 (ja) | 医薬組成物のための置換アルキル基含有チエノピリミジン | |
| JP6306035B2 (ja) | 医薬組成物のためのスルホキシミン置換キナゾリン | |
| JP6549109B2 (ja) | スルホキシイミン置換キナゾリンならびにｍｎｋ１および／またはｍｎｋ２キナーゼ阻害薬としてのその使用 | |
| JP5675614B2 (ja) | 医薬組成物用のチエノピリミジン | |
| EP2539344B1 (en) | Halogen or cyano substituted thieno[2,3-d]pyrimidines having mnk1/ mnk2 inhibiting activity for pharmaceutical compositions | |
| CN106061980A (zh) | 作为mknk1和mknk2抑制剂的噻吩并嘧啶 | |
| JP6457523B2 (ja) | 医薬組成物のためのスルホキシイミン置換キナゾリン | |
| JP6479854B2 (ja) | 医薬組成物のためのスルホキシイミン置換キナゾリン | |
| WO2015091156A1 (en) | Sulfoximine substituted pyrrolotriazines for pharmaceutical compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180417 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180417 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180511 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180813 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20181220 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190115 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190206 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6479854 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |